Last reviewed · How we verify
AZD4635 solid oral formulation - fasted — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AZD4635 solid oral formulation - fasted (AZD4635 solid oral formulation - fasted) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AZD4635 solid oral formulation - fasted TARGET | AZD4635 solid oral formulation - fasted | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AZD4635 solid oral formulation - fasted CI watch — RSS
- AZD4635 solid oral formulation - fasted CI watch — Atom
- AZD4635 solid oral formulation - fasted CI watch — JSON
- AZD4635 solid oral formulation - fasted alone — RSS
Cite this brief
Drug Landscape (2026). AZD4635 solid oral formulation - fasted — Competitive Intelligence Brief. https://druglandscape.com/ci/azd4635-solid-oral-formulation-fasted. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab